Posted inPress Releases
Exelixis Expands Oncology Strategy as Zanzalintinib Launch Nears
Exelixis is preparing for the next stage of its oncology business as the company balances the upcoming launch of zanzalintinib in metastatic colorectal cancer with efforts to expand its portfolio…









